Quarterly report pursuant to Section 13 or 15(d)

Organization and Nature of Business (Details)

v3.22.2.2
Organization and Nature of Business (Details)
3 Months Ended 9 Months Ended
Sep. 19, 2022
USD ($)
$ / shares
shares
Sep. 30, 2022
USD ($)
Jun. 30, 2022
USD ($)
Mar. 31, 2022
USD ($)
Sep. 30, 2021
USD ($)
Jun. 30, 2021
USD ($)
Mar. 31, 2021
USD ($)
Sep. 30, 2022
USD ($)
segment
Sep. 30, 2021
USD ($)
Dec. 31, 2021
USD ($)
$ / shares
Subsidiary, Sale of Stock [Line Items]                    
Number of operating segments | segment               1    
Share price | $ / shares $ 0.50                  
Gross proceeds $ 5,000,000.0             $ 4,576,600    
Net proceeds $ 4,500,000                  
Warrants exercise price percentage of IPO Price 125.00%                  
Warrants exercise price | $ / shares $ 0.625                 $ 12.50
Offering costs               82,680    
Net loss   $ 2,575,715 $ 3,667,255 $ 3,960,308 $ 4,109,982 $ 4,282,962 $ 3,056,033 10,203,278 $ 11,448,977  
Net cash used in operating activities               8,796,387 $ 10,511,438  
Accumulated deficit   $ 54,128,651           $ 54,128,651   $ 43,925,373
Minimum                    
Subsidiary, Sale of Stock [Line Items]                    
Period in which the company has to raise additional capital to complete clinical development               13 months    
Maximum                    
Subsidiary, Sale of Stock [Line Items]                    
Period in which the company has to raise additional capital to complete clinical development               15 months    
IPO | Maximum                    
Subsidiary, Sale of Stock [Line Items]                    
Shares issued | shares 10,000,000                  
Underwriter option                    
Subsidiary, Sale of Stock [Line Items]                    
Days to purchase additional shares granted to underwriters 45                  
Warrants exercise price | $ / shares $ 0.625                  
Number of warrants, as percentage of shares sold 5.00%                  
Underwriter option | Maximum                    
Subsidiary, Sale of Stock [Line Items]                    
Shares issued | shares 1,500,000